p90RSK Activation Promotes Epithelial-Mesenchymal Transition in Cisplatin-Treated Triple-Negative Breast Cancer Cells
	    		
		   		
		   			
		   		
	    	
    	 
    	10.4167/jbv.2019.49.4.221
   		
        
        	
        	
        	
        		- Author:
	        		
		        		
		        		
			        		Yujin JIN
			        		
			        		
			        		
			        			1
			        			
			        		
			        		
			        		
			        		
			        		;
		        		
		        		
		        		
			        		Kyung Sun HEO
			        		
			        		
		        		
		        		
		        		
		        		
		        			
			        		
			        		Author Information
			        		
		        		
		        		
			        		
			        		
			        			1. College of Pharmacy and Institute of Drug Research and Development, Chungnam National University, Daejeon, South Korea. kheo@cnu.ac.kr
			        		
		        		
	        		
        		 
        	
        	
        	
        		- Publication Type:Original Article
 
        	
        	
        		- Keywords:
        			
	        			
	        				
	        				
			        		
				        		Cisplatin;
			        		
			        		
			        		
				        		Epithelial-mesenchymal transition;
			        		
			        		
			        		
				        		p90RSK;
			        		
			        		
			        		
				        		Triple-negative breast cancer cells;
			        		
			        		
			        		
				        		Breast Cancer;
			        		
			        		
			        		
				        		Cisplatin;
			        		
			        		
			        		
				        		Epithelial-mesenchymal transition;
			        		
			        		
			        		
				        		p90RSK
			        		
			        		
	        			
        			
        		
 
        	
            
            	- MeSH:
            	
	        			
	        				
	        				
				        		
					        		Breast Neoplasms;
				        		
			        		
				        		
					        		Cadherins;
				        		
			        		
				        		
					        		Cisplatin;
				        		
			        		
				        		
					        		Drug Resistance;
				        		
			        		
				        		
					        		Epidermal Growth Factor;
				        		
			        		
				        		
					        		Epithelial-Mesenchymal Transition;
				        		
			        		
				        		
					        		Fluorescent Antibody Technique;
				        		
			        		
				        		
					        		Humans;
				        		
			        		
				        		
					        		MCF-7 Cells;
				        		
			        		
				        		
					        		Phosphotransferases;
				        		
			        		
				        		
					        		Plasmids;
				        		
			        		
				        		
					        		Polymerase Chain Reaction;
				        		
			        		
				        		
					        		Ribosomal Protein S6 Kinases, 90-kDa;
				        		
			        		
				        		
					        		RNA, Small Interfering;
				        		
			        		
				        		
					        		Snails;
				        		
			        		
				        		
					        		Triple Negative Breast Neoplasms;
				        		
			        		
				        		
					        		Up-Regulation
				        		
			        		
	        			
	        			
            	
            	
 
            
            
            	- From:Journal of Bacteriology and Virology
	            		
	            		 2019;49(4):221-229
	            	
            	
 
            
            
            	- CountryRepublic of Korea
 
            
            
            	- Language:English
 
            
            
            	- 
		        	Abstract:
			       	
			       		
				        
				        	p90 ribosomal S6 kinase (p90RSK), one of the downstream effectors in ERK1/2 pathways, shows high expression in human breast cancer tissues. However, its role in breast cancer development and drug resistance is not fully understood. Here, we demonstrate that Cis-DDP treatment failed to increase cytotoxicity in MDA-MB-231 cells compared to MCF-7 cells and p90RSK activation was involved in Cis-DDP-resistance to MDA-MB-231 cells. In the study, we found that inhibition of p90RSK expression or activation using a small interfering RNA (siRNA) or dominant-negative kinase mutant (DN-p90RSK) plasmid overexpression increased Cis-DDP-induced cytotoxicity of MDA-MB-231 cells, respectively. Mechanistically, we found that Cis-DDP resistance was associated with up-regulation of epithelial growth factor (EGF) expression and EGF treatment induced cancer survival signaling pathway including activation of ERK1/2, p90RSK, and Akt. We also examined the expression of epithelial-mesenchymal transition (EMT)-associated proteins using a reverse transition-quantitative PCR analysis. Cis-DDP treatment induced EMT by increasing the expression levels of N-cadherin, Snail, and Twist, while decreasing the expression levels of E-cadherin. Furthermore, we examined the epithelial marker, Zonula occludens-1 (ZO-1) using immunofluorescence analysis and found that Cis-DDP-inhibited ZO-1 expression was recovered by p90RSK deactivated condition. Therefore, we conclude that Cis-DDP resistance is involved in EMT via regulating the EGF-mediated p90RSK signaling pathway in MDA-MB-231 cells.